CSPC looks for HER2 white space
The company’s latest phase 3 for its biparatopic ADC is in colorectal cancer.
OnKure is no longer the only game in town
Cogent joins OnKure with a clinical-stage H1047Rm-specific PI3Kα inhibitor.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
AbbVie scales back its GARP ambitions
After a phase 3 push the livmoniplimab plan falters.
Eikon steps down into Nasdaq
With a slashed valuation the newly listed biotech heads for phase 3.
Novartis prunes its pipeline
An actinium-based backup and Werner helicase inhibitor are notable absences.
